Kim Hayeon, Huq M Saiful, Lalonde Ron, Houser Christopher J, Beriwal Sushil, Heron Dwight E
Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Appl Clin Med Phys. 2019 Nov;20(11):111-120. doi: 10.1002/acm2.12747. Epub 2019 Oct 29.
Varian Halcyon linear accelerator version 2 (The Halcyon 2.0) was recently released with new upgraded features. The aim of this study was to report our clinical experience with Halcyon 2.0 for a dual-isocenter intensity-modulated radiation therapy (IMRT) planning and delivery for gynecological cancer patients and examine the feasibility of in vivo portal dosimetry.
Twelve gynecological cancer patients were treated with extended-field IMRT technique using two isocenters on Halcyon 2.0 to treat pelvis and pelvic/or para-aortic nodes region. The prescription dose was 45 Gy in 25 fractions (fxs) with simultaneous integrated boost (SIB) dose of 55 or 57.5 Gy in 25 fxs to involved nodes. All treatment plans, pretreatment patient-specific QA and treatment delivery records including daily in vivo portal dosimetry were retrospectively reviewed. For in vivo daily portal dosimetry analysis, each fraction was compared to the reference baseline (1st fraction) using gamma analysis criteria of 4 %/4 mm with 90% of total pixels in the portal image planar dose.
All 12 extended-field IMRT plans met the planning criteria and delivered as planned (a total of 300 fractions). Conformity Index (CI) for the primary target was achieved with the range of 0.99-1.14. For organs at risks, most were well within the dose volume criteria. Treatment delivery time was from 5.0 to 6.5 min. Interfractional in vivo dose variation exceeded gamma analysis threshold for 8 fractions out of total 300 (2.7%). These eight fractions were found to have a relatively large difference in small bowel filling and SSD change at the isocenter compared to the baseline.
Halcyon 2.0 is effective to create complex extended-field IMRT plans using two isocenters with efficient delivery. Also Halcyon in vivo dosimetry is feasible for daily treatment monitoring for organ motion, internal or external anatomy, and body weight which could further lead to adaptive radiation therapy.
瓦里安Halcyon直线加速器版本2(Halcyon 2.0)最近发布,具有新的升级功能。本研究的目的是报告我们使用Halcyon 2.0为妇科癌症患者进行双等中心调强放射治疗(IMRT)计划和实施的临床经验,并探讨体内射野剂量测定的可行性。
12例妇科癌症患者采用扩展野IMRT技术,在Halcyon 2.0上使用两个等中心治疗盆腔和盆腔/腹主动脉旁淋巴结区域。处方剂量为45 Gy,分25次分割(fxs),对受累淋巴结同步推量(SIB)剂量为55或57.5 Gy,分25次分割。回顾性审查所有治疗计划、治疗前患者特异性质量保证和治疗实施记录,包括每日体内射野剂量测定。对于体内每日射野剂量测定分析,使用4%/4 mm的伽马分析标准,将每个分割与参考基线(第1分割)进行比较,门静脉图像平面剂量中90%的总像素参与比较。
所有12个扩展野IMRT计划均符合计划标准并按计划实施(共300次分割)。主要靶区的适形指数(CI)范围为0.99 - 1.14。对于危及器官,大多数都在剂量体积标准范围内。治疗实施时间为5.0至6.5分钟。在总共300次分割中,有8次分割(2.7%)的分次间体内剂量变化超过了伽马分析阈值。与基线相比发现,这8次分割在小肠充盈和等中心处的源皮距变化方面存在相对较大差异。
Halcyon 2.0能够有效地使用两个等中心创建复杂的扩展野IMRT计划,并高效实施。此外,Halcyon体内剂量测定对于器官运动、内部或外部解剖结构以及体重的每日治疗监测是可行的,这可能进一步推动自适应放射治疗。